Efficacy and tolerability assessment of cefprozil in children with acute otitis media.

Simple item page
dc.contributor.authorGupta, Nomeetaen_US
dc.contributor.authorBagga, Viveken_US
dc.contributor.authorParmar, Bharat Jen_US
dc.contributor.authorKar, Kishaloyen_US
dc.contributor.authorMukherjee, Abhijiten_US
dc.contributor.authorMehta, Sandipen_US
dc.contributor.authorMoharana, Ashok Ken_US
dc.date.accessioned2004-04-27en_US
dc.date.accessioned2009-05-30T13:39:31Z
dc.date.available2004-04-27en_US
dc.date.available2009-05-30T13:39:31Z
dc.date.issued2004-04-27en_US
dc.description.abstractYoung children contract as many as six to eight upper respiratory tract viral infections per year, and these infections frequently lead to secondary bacterial infections such as acute otitis media and sinusitis. Cefprozil is an orally active third generation cephalosporin which has demonstrated activity against the gram-positive organisms Streptococcus pyogenes, pneumoniae and agalactiae and against methicilin-susceptible Staphylococcus aureus. Cefprozil is also active against various gram-ves and certain anaerobic organisms, and is stable to hydrolysis by a number of b-lactamases. Present study is an effort to study the efficacy and safety of cefprozil in children with acute otitis media. Three hundred and thirty four children aged 6 months through 12 years with clinical symptoms and tympanic membrane signs of AOM received cefprozil 30 mg/kg/day in two divided doses per day for 10 days. Clinically, 96.6% patients were cured, 2.4% improved and there was failure of therapy in 1% of the patients. There was no need for any rescue medication and any change in antibiotic in any patient. A satisfactory bacteriological outcome was (i.e. cure, presumed cure, and cure plus reinfection with a different pathogen) was achieved in 95% of patients. In conclusion, cefprozil is a well tolerated and effective drug for acute otitis media in children. Moreover, its expanded spectrum of activity, ability to achieve adequate concentrations in tissues, suitability for twice-daily dosing, and proven tolerability suggest that it is a better alternative to agents conventionally used in acute otitis media.en_US
dc.description.affiliationDepartment of Pediatrics, Batra Hospital & Research Centre, New Delhi, India.en_US
dc.identifier.citationGupta N, Bagga V, Parmar BJ, Kar K, Mukherjee A, Mehta S, Moharana AK. Efficacy and tolerability assessment of cefprozil in children with acute otitis media. Indian Journal of Pediatrics. 2004 Apr; 71(4): 319-24en_US
dc.identifier.urihttps://imsear.searo.who.int/handle/123456789/81904
dc.language.isoengen_US
dc.source.urihttps://medind.nic.in/icb/icbai.shtmlen_US
dc.subject.meshAcute Diseaseen_US
dc.subject.meshAnti-Bacterial Agents --administration & dosageen_US
dc.subject.meshCephalosporins --administration & dosageen_US
dc.subject.meshChilden_US
dc.subject.meshChild, Preschoolen_US
dc.subject.meshFemaleen_US
dc.subject.meshHumansen_US
dc.subject.meshInfanten_US
dc.subject.meshMaleen_US
dc.subject.meshOtitis Media --drug therapyen_US
dc.subject.meshProspective Studiesen_US
dc.subject.meshTreatment Outcomeen_US
dc.titleEfficacy and tolerability assessment of cefprozil in children with acute otitis media.en_US
dc.typeClinical Trialen_US
dc.typeJournal Articleen_US
dc.typeMulticenter Studyen_US
Files
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.79 KB
Format:
Plain Text
Description:
Download
Collections
Indian Journal of Pediatrics